Latest On Aytu BioScience, Inc (AYTU):
About Aytu BioScience, Inc (AYTU):
Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado.
General
- Name Aytu BioScience, Inc
- Symbol AYTU
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 75
- Last Split Factor1:10
- Last Split Date2020-12-09
- Fiscal Year EndJune
- IPO Date2017-02-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://aytubio.com
Valuation
- Forward PE 10.7
- Price/Sales (Trailing 12 Mt.) 1.49
- Price/Book (Most Recent Quarter) 1.22
- Enterprise Value Revenue 1.47
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.05
- Next Year EPS Estimate -$0.83
- Next Quarter EPS Estimate -$0.57
- Profit Margin -43%
- Operating Margin -38%
- Return on Assets -10%
- Return on Equity -34%
- Revenue 51.68 million
- Earnings Per Share -$3.48
- Revenue Per Share $5.14
- Gross Profit 20.08 million
- Quarterly Earnings Growth 377%
Highlights
- Market Capitalization 176.68 million
- EBITDA -14119570
- Analyst Target Price $20.6
- Book Value Per Share $6.30
Share Statistics
- Shares Outstanding 17.88 million
- Shares Float 14.74 million
- % Held by Insiders 237%
- % Held by Institutions 25.98%
- Shares Short 372604
- Shares Short Prior Month 340661
- Short Ratio 0.62
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta -0.24
- 52 Week High $22.2
- 52 Week Low $5.86
- 50 Day Moving Average 8.14
- 200 Day Moving Average 9.07
Dividends
- Dividend Date 2020-12-09
- ExDividend Date N/A
- Dividend Yield 0%
Aytu BioScience, Inc (AYTU) Dividend Calendar:
AYTU's last dividend payment was made to shareholders on December 9, 2020.
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
Aytu BioScience, Inc (AYTU) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2020-12-31 | 2021-02-11 | $N/A | -$0.45 | -$0.44 | -2.27% |
2020-09-30 | 2020-10-06 | $N/A | -$0.23 | -$0.35 | 33.6% |
2020-06-30 | 2020-09-24 | $N/A | -$0.20 | -$0.35 | 42.86% |
2020-03-31 | 2020-05-15 | $8.16 million | -$1.50 | -$0.50 | -200% |
2019-12-31 | 2020-02-13 | $3.18 million | -$0.10 | -$2.45 | 95.92% |
2019-09-30 | 2019-11-14 | $1.44 million | -$3.20 | -$2.75 | -16.36% |
2019-06-30 | 2019-09-26 | $1.72 million | -$4.21 | -$3.30 | -27.45% |
2019-03-31 | 2019-05-14 | $2.38 million | -$5.00 | -$5.80 | 13.79% |
2018-12-31 | 2019-02-07 | $1.8 million | -$7.20 | -$3.95 | -82.28% |
2018-09-30 | 2018-11-07 | $1.43 million | -$19.60 | -$14.50 | -35.17% |
2018-06-30 | 2018-09-06 | $925125 | $0.31 | ||
2018-03-31 | 2018-05-14 | $607473 | -$48.00 | -$200.00 | 76% |
2017-12-31 | 2018-02-08 | $1.05 million | -$178.00 | -$356.00 | 50% |
2017-09-30 | 2017-11-09 | $1.08 million | -$352.00 | -$404.00 | 12.87% |
2017-06-30 | 2017-08-31 | $836000 | -$1,340.00 | -$1,720.00 | 22.09% |
2017-03-31 | 2017-05-11 | $894000 | -$1,920.00 | -$1,700.00 | -12.94% |
2016-12-31 | 2017-02-09 | $794000 | -$2,440.00 | -$1,733.33 | -40.77% |
2016-09-30 | 2016-11-07 | $698000 | -$4,680.00 | -$2,573.33 | -81.87% |
2016-06-30 | 2016-09-01 | $937000 | -$9,092.00 | -$3,120.00 | -191.41% |
2016-03-31 | 2016-05-04 | $668000 | -$1,854.38 | ||
2015-12-31 | 2015-12-31 | $470000 | -$11,217.23 | ||
2015-09-30 | 2015-09-30 | $487000 | -$7,661.95 | ||
2015-03-31 | 2015-03-31 | $23000 | -$24,108.10 | ||
2014-12-31 | 2015-02-28 | $29000 | -$988.87 | ||
2014-09-30 | 2014-11-30 | $27000 | -$1,599.89 | ||
2014-06-30 | 2014-08-31 | $59000 | -$1,140.71 | ||
2014-03-31 | 2014-05-31 | $N/A | -$1,350.18 | ||
2013-12-31 | 2014-02-28 | $N/A | -$2,637.63 | ||
2013-09-30 | 2013-11-30 | $N/A | -$1,961.85 | ||
2013-06-30 | 2013-08-31 | $750 | -$1,260.46 | ||
2013-03-31 | 2013-05-31 | -$1,585.35 | |||
2012-12-31 | 2013-02-28 | -$1,632.44 | |||
2012-09-30 | 2012-11-30 | -$2,385.94 | |||
2012-06-30 | 2012-08-31 | -$2,184.62 | |||
2012-03-31 | 2012-05-31 | -$1,442.35 | |||
2011-12-31 | 2012-02-29 | -$1,229.77 | |||
2011-09-30 | 2011-11-30 | $N/A | -$2,413.06 | ||
2011-06-30 | 2011-08-31 | -$10,247.12 | |||
2011-03-31 | 2011-05-31 | -$2,871.48 | |||
2010-12-31 | 2011-02-28 | -$3,825.84 | |||
2010-09-30 | 2010-11-30 | -$2,966.23 | |||
2010-06-30 | 2010-08-31 | -$2,356.07 | |||
2010-03-31 | 2010-05-31 | -$2,495.40 | |||
2009-12-31 | 2010-02-28 | -$2,058.53 | |||
2009-09-30 | 2009-11-30 | -$3,211.20 | |||
2009-06-30 | 2009-08-31 | -$1,926.12 | |||
2009-03-31 | 2009-05-31 | -$1,633.78 | |||
2008-12-31 | 2009-02-28 | -$2,738.65 | |||
2008-09-30 | 2008-11-30 | -$3,833.03 |
Aytu BioScience, Inc (AYTU) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
Aytu BioScience, Inc (AYTU) Chart:
Aytu BioScience, Inc (AYTU) News:
Below you will find a list of latest news for Aytu BioScience, Inc (AYTU) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aytu BioScience, Inc (AYTU) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Latest AYTU Trades:
Date | Shares | Price |
---|---|---|
Jun 13, 2022 7:59 PM EST | 20 | $0.4782 |
Jun 13, 2022 7:59 PM EST | 80 | $0.4782 |
Jun 13, 2022 7:59 PM EST | 40 | $0.4782 |
Jun 13, 2022 7:59 PM EST | 49 | $0.4782 |
Jun 13, 2022 7:59 PM EST | 100 | $0.4782 |
Aytu BioScience, Inc (AYTU) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/0001213900-20-016604-index.htm |
2020-02-27 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1385818/000000000020001798/0000000000-20-001798-index.htm |
2020-06-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1385818/000000000020005255/0000000000-20-005255-index.htm |
2020-06-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1385818/000000000020005256/0000000000-20-005256-index.htm |
2020-03-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm |
2020-03-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002440/0000919574-20-002440-index.htm |
2020-04-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002814/0000919574-20-002814-index.htm |
2020-04-08 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002815/0000919574-20-002815-index.htm |
2020-04-29 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1385818/000091957420003056/0000919574-20-003056-index.htm |
2020-04-29 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm |
2020-04-27 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1385818/000110465920051622/0001104659-20-051622-index.htm |
2020-02-27 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1385818/000121390020004915/0001213900-20-004915-index.htm |
2020-02-28 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1385818/000121390020005050/0001213900-20-005050-index.htm |
2020-03-02 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1385818/000121390020005175/0001213900-20-005175-index.htm |
2020-03-04 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1385818/000121390020005421/0001213900-20-005421-index.htm |
2020-03-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1385818/000121390020006183/0001213900-20-006183-index.htm |
2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020006187/0001213900-20-006187-index.htm |
2020-03-13 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1385818/000121390020006269/0001213900-20-006269-index.htm |
2020-03-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020006311/0001213900-20-006311-index.htm |
2020-03-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1385818/000121390020007010/0001213900-20-007010-index.htm |
2020-03-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020007021/0001213900-20-007021-index.htm |
2020-03-23 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1385818/000121390020007140/0001213900-20-007140-index.htm |
2020-03-30 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1385818/000121390020007828/0001213900-20-007828-index.htm |
2020-04-03 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1385818/000121390020008577/0001213900-20-008577-index.htm |
2020-04-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1385818/000121390020008861/0001213900-20-008861-index.htm |
2020-06-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020013839/0001213900-20-013839-index.htm |
2020-06-08 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1385818/000121390020014381/0001213900-20-014381-index.htm |
2020-06-08 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1385818/000121390020014383/0001213900-20-014383-index.htm |
2020-06-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020014833/0001213900-20-014833-index.htm |
2020-06-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1385818/000121390020014842/0001213900-20-014842-index.htm |
2020-06-12 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1385818/000121390020014847/0001213900-20-014847-index.htm |
2020-07-02 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000121390020016604/0001213900-20-016604-index.htm |
2020-09-28 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1385818/000121390020028696/0001213900-20-028696-index.htm |
2020-03-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1385818/000153561020000080/0001535610-20-000080-index.htm |
2020-04-27 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000157856320000020/0001578563-20-000020-index.htm |
2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420002568/0001654954-20-002568-index.htm |
2020-03-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420002843/0001654954-20-002843-index.htm |
2020-03-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420002956/0001654954-20-002956-index.htm |
2020-03-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420003132/0001654954-20-003132-index.htm |
2020-04-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420003646/0001654954-20-003646-index.htm |
2020-04-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420003771/0001654954-20-003771-index.htm |
2020-04-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420003829/0001654954-20-003829-index.htm |
2020-04-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004096/0001654954-20-004096-index.htm |
2020-04-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004130/0001654954-20-004130-index.htm |
2020-04-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004187/0001654954-20-004187-index.htm |
2020-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004215/0001654954-20-004215-index.htm |
2020-04-23 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004311/0001654954-20-004311-index.htm |
2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004374/0001654954-20-004374-index.htm |
2020-05-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420004762/0001654954-20-004762-index.htm |
2020-05-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420005000/0001654954-20-005000-index.htm |
2020-05-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420005474/0001654954-20-005474-index.htm |
2020-05-15 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1385818/000165495420005522/0001654954-20-005522-index.htm |
2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006576/0001654954-20-006576-index.htm |
2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006581/0001654954-20-006581-index.htm |
2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006582/0001654954-20-006582-index.htm |
2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006583/0001654954-20-006583-index.htm |
2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006584/0001654954-20-006584-index.htm |
2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006585/0001654954-20-006585-index.htm |
2020-06-29 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420007046/0001654954-20-007046-index.htm |
2020-08-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1385818/000165495420009234/0001654954-20-009234-index.htm |
2020-10-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1385818/000165495420010889/0001654954-20-010889-index.htm |
2020-10-06 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1385818/000165495420010891/0001654954-20-010891-index.htm |
2020-02-28 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1385818/999999999520000446/9999999995-20-000446-index.htm |
2020-06-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1385818/999999999520001463/9999999995-20-001463-index.htm |
2020-06-17 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1385818/999999999520001464/9999999995-20-001464-index.htm |
Aytu BioScience, Inc (AYTU) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aytu BioScience, Inc (AYTU). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 237%Institutional Ownership: 2598%
Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
---|---|---|---|---|---|---|---|---|
2020-04-27 | ARMISTICE CAPITAL, LLC | Director | Sell | 0.00 | 0.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm | ||
2020-04-27 | ARMISTICE CAPITAL, LLC | Director | Sell | 5,108,921.00 | 1.82 | 9,298,236.22 | 0.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm |
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Sell | 0.00 | 1.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Sell | 2,456,822.00 | 0.99 | 2,432,253.78 | 1.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm |
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 1,918,587.00 | 10,203,867.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 0.00 | 15,203,867.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 5,000,000.00 | 1.00 | 5,000,000.00 | 15,203,867.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm |
2020-06-08 | Gary Cantrell | Director | Buy | 10,000.00 | 162,840.00 | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006582/0001654954-20-006582-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 0.00 | 19,609,276.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 4,403,409.00 | 1.00 | 4,403,409.00 | 19,609,276.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm |
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 3,907,165.00 | 1.50 | 5,860,747.50 | 22,026,802.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm |
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Buy | 0.00 | 22,036,802.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Sell | 0.00 | 2,456,823.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm | ||
2020-03-10 | ARMISTICE CAPITAL, LLC | Director | Sell | 19,569,979.00 | 1.47 | 28,767,869.13 | 2,456,823.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420002393/0000919574-20-002393-index.htm |
2020-04-27 | ARMISTICE CAPITAL, LLC | Director | Buy | 0.00 | 5,108,921.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm | ||
2020-04-27 | ARMISTICE CAPITAL, LLC | Director | Buy | 5,000,000.00 | 1.25 | 6,250,000.00 | 5,108,921.00 | https://www.sec.gov/Archives/edgar/data/1385818/000091957420003060/0000919574-20-003060-index.htm |
2020-06-08 | David A Green | Chief Financial Officer | Buy | 250,000.00 | 521,250.00 | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006585/0001654954-20-006585-index.htm | ||
2020-04-15 | Cerecor Inc. | 10% Share Holder | Sell | 92,777.00 | 1.55 | 144,091.96 | 9,713,068.00 | https://www.sec.gov/Archives/edgar/data/1385818/000157856320000020/0001578563-20-000020-index.htm |
2020-06-08 | Joshua R. Disbrow | Chief Executive Officer | Buy | 450,000.00 | 975,048.00 | https://www.sec.gov/Archives/edgar/data/1385818/000165495420006583/0001654954-20-006583-index.htm |